RSS

Alzheimer's

According to a new study from the University of Eastern Finland and the German Center for Neurodegenerative Diseases, DZNE, antiepileptic drugs are associated with an increased risk of Alzheimer’s disease and dementia. more

News

After the successful completion of the Phase I trial, Araclon Biotech and TFS International have announced a continuation of their partnership to advance the trial of the Alzheimer’s disease (AD) vaccine ABvac40 into Phase II. more

News

A drug that was believed to be a promising new therapeutic option for suffers of Alzheimer’s (idalopirdine) — from the Danish pharma company, Lundbeck — has failed to show clinical benefit in three randomised trials. more

News

A clinical study, performed by researchers from the UK and China, has demonstrated that novel triple receptor agonists (TAs) originally developed to treat Type 2 diabetes, significantly reversed memory loss in a mouse model of Alzheimer’s disease. more

News

Axovant Sciences, a clinical-stage biopharmaceutical company, has revealed negative topline results of its Phase III MINDSET trial in Alzheimer’s disease, but the CEO has stressed that the company will continue advancing its pipeline more

News

A recent study from the University of Eastern Finland has demonstrated that proton pump inhibitors, commonly used as antiulcer drugs in older patients, do not increase the risk of Alzheimer’s disease. more

News

Professor Giovanna Mallucci and her team have identified two drugs that can block the death of brain cells in mice models of neurodegeneration. This research builds on the earlier breakthrough by the team four years ago. more

News

Results from studies of ALZ-801 and its active molecule tramiprosate support the study design for the clinical programme, reports Alzheon. more

News

According to business intelligence provider GBI Research, pharmaceuticals company Roche will be the biggest mover in the neurodegenerative drugs space over the next five years. more

News

A recent study from the University of Eastern Finland has shown that the use of benzodiazepines and similar drugs was associated with a 20% increased risk of stroke for patients with Alzheimer’s disease. more

News

A supercharged version of the acid derived from our Christmas dinner veg is the basis of new research aimed at developing a new drug to treat Alzheimer’s disease. more

News

Global healthcare company Lilly has announced the results of a phase 3 clinical trial, designed to test the efficacy of a drug to slow the effects of Alzheimer’s. more

News

Biopharmaceutical company PhoreMost has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. more

News

Biopharmaceutical company Probiodrug AG have announced the first results of a preclinical combination trial targeting pGlu-Abeta, a peptide thought to play a role in Alzheimer’s disease progression. more

News

A clinical trial of a new drug shows promising results for those suffering early-stage Alzheimer’s more

News

Probiodrug, a biopharmaceutical company developing therapeutic products to treat Alzheimer's disease has entered into a collaboration with Dutch biotech Crossbeta Biosciences more

News

Concert Pharmaceuticals has achieved a $2 million (£1.3m) milestone under its development and license agreement with Avanir Pharmaceuticals for the phase three initiation of AVP-786 for agitation in patients with Alzheimer’s more

News

University College London (UCL) research shows that withdrawing donepezil from people with advanced stages of Alzheimer’s doubled their risk of being placed in a nursing home within a year more

News

Last week we reported on Eli-Lilly’s breakthrough Alzheimer’s disease drug solanezumab. This week we look back at the history behind five existing treatments on the market. more

News

Following hot on the heels of yesterday’s announcement that Eli-Lilly’s drug solanezumab heralded a breakthrough in the treatment of Alzheimer’s, the EPM team has done some digging and presents four additional newsworthy developments in the field. more

News